knowledge -WSS

knowledge

author：hotspot 2025-08-26 10:52:51 - browse：9

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： The world needs the new pandemic treaty

WSS

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

WATCH: Why do our ears pop?

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Ukraine seeks to reclaim its role as a hub for clinical trials

J&J reports mixed data on next

knowledge

knowledge

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

Reporting on presidential health from Reagan to Trump and Biden

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

The high cost of giving birth even with insurance

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

How one medical school became remarkably diverse

Decentralized clinical trials need collaboration to achieve wider use

focus

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Stroke rates rising, especially in working

In 'major milestone,' FDA approves first cell therapy for solid tumors

J&J reports mixed data on next

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

explore

hotspot

focus

focus